[Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer]

[Article in Russian]

Comparative Study

[Article in Russian]

V A Gorbunova et al. Vopr Onkol. 2002.

. 2002;48(6):695-9.

No abstract available

Similar articles

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Ortega A, et al. Gynecol Oncol. 1997 Sep;66(3):454-63. doi: 10.1006/gyno.1997.4786. Gynecol Oncol. 1997. PMID: 9299261
[Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Gorbunova VA, Khokhlova SV, Besova NS, Orel NF, Kuznetsov VV, Bliumenberg AG, Smirnova NB, Chekalova MA, Sinitsyna ME, Poddubnyĭ BK. Gorbunova VA, et al. Vopr Onkol. 2001;47(5):1-6. Vopr Onkol. 2001. PMID: 11799946 Clinical Trial. Russian. No abstract available.
Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?
Covens A, Boucher S, Roche K, Macdonald M, Pettitt D, Jolain B, Souetre E, Rivière M. Covens A, et al. Cancer. 1996 May 15;77(10):2086-91. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2086::AID-CNCR18>3.0.CO;2-R. Cancer. 1996. PMID: 8640674
Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
Messori A, Trippoli S. Messori A, et al. Anticancer Drugs. 1998 Nov;9(10):909-16. doi: 10.1097/00001813-199811000-00010. Anticancer Drugs. 1998. PMID: 9890702 Review.
Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP 3rd. McGuire WP 3rd. J Clin Oncol. 2003 May 15;21(10 Suppl):133s-135s. doi: 10.1200/JCO.2003.01.066. J Clin Oncol. 2003. PMID: 12743128 Review.